

PERSONAL INFORMATION



Paolo Bironzo

📍 30, Via Montebello, Torino, 10124, Italy

☎ +39 0119026865

✉ paolo.bironzo@unito.it

🌐 https://www.dep-oncology.unito.it/do/docenti.pl/Show?_id=pbironzo#tab-profilo

Male | 05/04/1985 | italian

Enterprise	University	EPR
<input type="checkbox"/> Management Level	<input type="checkbox"/> Full professor	<input type="checkbox"/> Research Director and 1st level Technologist / First Researcher and 2nd level Technologist
<input type="checkbox"/> Mid-Management Level	<input type="checkbox"/> Associate Professor	<input type="checkbox"/> Level III Researcher and Technologist
<input type="checkbox"/> Employee / worker level	<input checked="" type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator	<input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator

WORK EXPERIENCE

2021-ongoing

Assistant Professor

University of Torino (Torino, Italy)

- Clinical and translational research on thoracic tumors

2018-2021

Research Fellow

University of Torino (Torino, Italy)

- Clinical and translational research on thoracic tumors

EDUCATION AND TRAINING

2017-2020

PhD programme on Complex Systems for Life Sciences

University of Torino (Torino, Italy)

2017

Medical Oncology specialization

University of Torino (Torino, Italy)

2010

Medicine Degree

University of Torino (Torino, Italy)

WORK ACTIVITIES

Awards

Associazione Italiana di Oncologia Medica (AIOM) award for Translational Research in Thoracic Oncology (2017)

Editorial Activity

Member of the editorial board of the Journal of Thoracic Oncology (2020 IF:15.61) and Clinical Lung Cancer (2020 IF: 4.785).

Invited presentations

Regional, National and International Meeting including:

- European Lung Cancer Congress 2022, Virtual Event, March 30h – April 2nd 2022
- Congresso Nazionale AIOM 2021, Virtual Event, October 22-24th 2021
- “Gli oncologi del Piemonte e della Valle d’Aosta: novità e controversie post ASCO ed ESMO 2021”. Hybrid event, October 1st 2021
- “Convegno Regionale CIPOMO Piemonte e Valle d’Aosta. La comunicazione in oncologia: come sta cambiando in tempo di COVID”. Hybrid event, September 17th 2021

- “2021 News in Oncology: from USA to Italy”, AIOM Virtual Event, June 18-19th 2021
- “COMU torna da Chicago 2020”, Virtual Event, June 5-6th 2020
- “La rete oncologica del Piemonte e della Valle d’Aosta. Post ESMO 2019- Highlights”. Torino, October 18th 2019
- “La rete oncologica del Piemonte e della Valle d’Aosta: novità e controversie post- ASCO 2019”. Torino, June 13th 2019
- “La qualità di vita in oncologia. Convegno Scientifico Nazionale”. Roma, Auditorium del Ministero della Salute, February 27th 2019
- “Best of WCLC 2018”. Torino, October 1st 2018
- “AIOM post ASCO Review: updates and news from the Annual Meeting in Chicago”. Milano, June 15,16th 2018
- “COMU racconta l’ASCO”. Torino, June 8,9th 2018
- “Riunione nazionale COMU”. Torino, February 2,3th 2018
- “Convegno AIOM regionale Piemonte e Valle d’Aosta. Dall’oncologia alla medicina legale e ritorno: luci e ombre nella gestione del paziente oncologico.” Torino, October 20th 2017.
- “Convegno AIOM regionale Piemonte e Valle d’Aosta. Le reti oncologiche regionali: realtà, problematiche e prospettive”. Torino, May 18th 2017
- “La rete oncologica del Piemonte e della Valle d’Aosta: novità e controversie ASCO 2016”. Torino, June 17th 2016
- “2015: News in Oncology- Congresso Nazionale AIOM Giovani”. Perugia, July 10-11th 2015
- “La rete oncologica del Piemonte e della Valle d’Aosta: novità e controversie ASCO 2015”. Torino, June 11th 2015

Grants Institutional Grant by Roche for TANGIBLE study (2020)
Institutional Grant by Pfizer for IMPACT study (2021)

Patents None

ADDITIONAL INFORMATION

Publications **Total number of publications in peer-review journals: 63**

Total impact factor: 19.28

Total number of citations: 1273

H index (Scopus): 17

Relevant publications:

- Mazières J, Drilon A, Lusque A, [...], **Bironzo P**, [...], Gautschi O. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol 2019;30(8):1321-28.
- Bulik-Sullivan B, Busby J, Palmer CD, [...], **Bironzo P**, [...], Yelensky R. Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification. Nat Biotechnol 2018 [Epub ahead of print].
- Duruisseaux M, Martinize-Cardùs A, Calleja-Cervantes ME, [...], **Bironzo P**, [...], Esteller M. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicenter retrospective analysis. Lancet Respir Med 2018;6:771-81.
- Lo Iacono M, Monica V, Righi L, [...], **Bironzo P**, [...], Scagliotti GV.

“Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study”, J Thorac Oncol. 2015;10:492-9

- **Bironzo P**, Di Maio M. A review of guidelines for lung cancer. J Thorac Dis 2018;10(suppl 13):S1556-S1563.
- Marandino L, La Salvia A, Sonetto C, [...], **Bironzo P**, Di Maio M. Deficiencies in health-related quality of life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016. Ann Oncol 2018;29:2288-95.
- Cortellini A, Tiseo M, Banna GL, [...], **Bironzo P**, [...], Porzio G. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and PD-L1 expression of $\geq 50\%$. Cancer Immunol Immunother.2020 [Epub ahead of print]
- Riganti C, Lingua MF, Saroglio IC, [...], **Bironzo P**, [...], Taulli R. “Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment”. Oncoimmunology 2017;7(3):e1398874
- Scagliotti GV, **Bironzo P**, Vansteenkiste JF "Addressing the unmet need in lung cancer: the potential of immuno-oncology" Cancer Treat Rev.2015;41(6):465-75.
- Salaroglio IC, Kopecka J, Napoli F, [...], **Bironzo P**, [...], Riganti C. Potential diagnostic and prognostic role of micro-environment in malignant pleural mesothelioma. J Thorac Oncol 2019;14(8):1458-71.
- Betti M, Aspesi A, Ferrante D, [...], **Bironzo P**, [...], Dianzani I. Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes. Genes Chromosomes Cancer 2018. 57(11):573-83.
- Tagliamento M, **Bironzo P**, Novello S. New emerging targets in cancer immunotherapy: the role of VISTA. ESMO Open.2020;4(suppl 3):e000683
- Schena M, Guarrera S, Buffoni L, [...], **Bironzo P**, Matullo G. “DNA repair gene expression level in peripheral blood and tumour tissue from non-small cell lung cancer and head and neck squamous cell cancer patients”, DNA Repair. 2012; 11(4): 374-380